June 7, 2021 ~ TrialSite News
DGHS Hatchet Chops Ivermectin Nationally While Positioning Unproven Tocilizumab Despite Success of Uttar Pradesh—How will ICMR & AIMS Weigh In?
Power, politics, and economics are alive and well in India as apparently as quickly as select national health authorities in the world’s most second populated nation and fifth largest economy as measured by gross domestic product (GDP) included ivermectin in the national guidelines, the recommendation was just as quickly rescinded despite what appears to be tremendous success in states such as Uttar Pradesh, as TrialSite has recently reported. TrialSite has chronicled a remarkable turnaround that’s included the use of ivermectin and doxycycline-based home medicine kits in Uttar Pradesh and a few other states. On April 22, the use of ivermectin was formalized at the national level by All Institute of India Medical Science (AIIMS) and the Indian Council of Medical Research (ICMR) as reported in TrialSite. But in a national movement to hatchet that recommendation, the Union Health Ministry and Family Welfare’s directorate general of health services known as DGHS changed the guidelines again to cease use of Ivermectin and Doxycycline for COVID-19 treatment, dropping all medicines except for antipyretic and antitussives for asymptomatic and mild cases, reports local media. But this seeming power play perhaps represents a significant fissure between authorities and experts as it reveals monumental economic, political and medicinal tensions as the ICMR, the nation’s main health agency in the war against SARS-CoV-2, hasn’t approved of these changes as of yet.